Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate adjunctive treatment for acute early schizophrenia or schizoaffective disorder
MOH_2017-12-06_002008Phase 2Not yet recruiting
- Sponsor
- פרופ' מרק וייזר
- Start
- Jun 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia, schizoaffective disorder and Schizophrenia Spectrum Disorders (SSD) comparing Methotrexate add-on arm with Placebo add-on arm (2 arms). Planned start Jun 2017; status: not yet recruiting.
02
Drugs
methotrexate
03
Conditions
schizophreniaschizoaffective disorderSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on MOH_2017-12-06_002008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-06_002008.